Zim Laboratories Limited has informed the Exchange about EU GMP Inspection Outcome
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zim Laboratories' manufacturing facility in Kalmeshwar, Nagpur, was inspected by German and Portuguese regulatory authorities from 30 June to 4 July 2025 as part of the EU GMP compliance process. The inspection report dated 31 July 2025 found the facility non-compliant with EU GMP requirements, identifying 2 critical, 8 major, and 18 minor deficiencies. The company must submit a binding Corrective and Preventive Action (CAPA) plan within 4 weeks, after which a re-inspection will be conducted. The company has stated it remains committed to resolving the issues and achieving full compliance.
This is a negative development for shareholders — EU GMP non-compliance can restrict the company's ability to supply products to European markets, potentially affecting revenue and export earnings. The stock may face short-term pressure until clarity emerges on the CAPA implementation and re-inspection outcome.